Workshop to explore the impact of NDI draft guidance, final GRAS rule for probiotics

By Stephen Daniells

- Last updated on GMT

©  iStock / Jezperklauzen
© iStock / Jezperklauzen

Related tags: Probiotic

A workshop hosted by the International Probiotics Association (IPA) in Washington, DC will tackle some of the key issues facing the probiotics sector, including positions from FDA and FTC on NDIs and claims substantiation.

The workshop, which will take place on November 2 at the College Park Marriott Hotel & Conference Center in Hyattsville, MD, will also explore best practices, cutting edge analytical techniques, and current market data.

“Interest in the category is continually growing, and probiotics are in the spotlight because of the science, the health benefits and the market growth,”​ said George Paraskevakos, IPA’s executive director. “Regulators have realized that probiotics are a unique category​.

Presentations by experts from the FDA and FTC include:
Genomic analysis of beneficial microbes - supporting industry and regulation with innovative science​ - Dr Chris Elkins, FDA
The Regulation of Probiotic Claims in Advertising: Don’t Let it Bug You ​- Richard L. Cleland, FTC
NDI draft guidance comments​ - Dr Cara Welch, FDA
The GRAS final rule: Overview and implications for FDA’s GRAS notification process​ - Richard Bonnette, FDA

“Monica Feldman from Euromonitor will discuss the scope and size of the sector because the government needs to know what it’s dealing with,” ​explained Paraskevakos, “and that includes the direction of the sector, from dietary supplements to functional foods and into targeted applications that would require an IND.”

“The workshop represents an excellent opportunity for industry and government to collaborate on the development of standards, best practices, and guidelines.”

The event is limited to 150 places.For more information and to register, please click HERE​.

The full program can be downloaded here: 

IPA_ProbioticWS

IPA_ProbioticWS.pdf 0.32 MB

The retail value of probiotic dietary supplements is $1.7 billion in the US, according to data from Euromonitor, and expected to grow to $3 billion by 2020.

Related news

Related products

show more

Bacillus Coagulans SNZ 1969; Efficacy & Stability

Bacillus Coagulans SNZ 1969; Efficacy & Stability

Sanzyme Biologics | 17-Feb-2020 | Technical / White Paper

SNZ 1969 has been shown to help reduce occasional gut discomfort, promote regularity, reduce occasional diarrhea, reduce occasional heartburn, and promote...

B. breve B-3 – the weight management probiotics

B. breve B-3 – the weight management probiotics

Morinaga Milk Industry Co., Ltd. | 20-Nov-2019 | Clinical Study

Morinaga Milk’s Human-Residential Bifidobacteria (HRB) probiotics possess superior physiological benefits and are typically well-suited for human consumption....

HRB are ideal probiotics for human health

HRB are ideal probiotics for human health

Morinaga Milk Industry Co., Ltd. | 20-Nov-2019 | Technical / White Paper

Evidence is accumulated that the physiological benefits of probiotics bifidobacteria are not only strain-specific but also dependent on their residential...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars